Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Sep 18:12:3003-3011.
doi: 10.2147/DDDT.S175887. eCollection 2018.

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

Hongzhen Zhong  1 , Tianbiao Zhou  1 , Hongyan Li  2 , Zhiqing Zhong  1
Affiliations
Meta-Analysis

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

Hongzhen Zhong et al. Drug Des Devel Ther. .

Abstract

Introduction: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.

Methods: Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence of adverse events (AEs) were extracted and pooled using Review Manager Version 5.3.

Results: Data from nine selected studies were extracted. Meta-analysis of the included studies showed that HIF stabilizers reduced ferritin and hepcidin levels and increased Hb level and TIBC in NDD-CKD patients. However, HIF stabilizers only increased TIBC, and did not affect ferritin, hepcidin, and Hb levels in DD-CKD patients. Furthermore, no notable differences in AEs and severe AEs between NDD-CKD and DD-CKD patients were detected.

Conclusion: HIF stabilizers are effective for the treatment of anemia in NDD-CKD patients and safe for short-term use.

Keywords: anemia; chronic kidney disease; hypoxia-inducible factor stabilizer; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Association between HIF stabilizers and Hb in patients with CKD. Notes: (A) NDD-CKD subgroup. (B) DD-CKD subgroup. Abbreviations: HIF, hypoxia-inducible factor; Hb, hemoglobin; CKD, chronic kidney disease; NDD-CKD, non-dialysis-dependent chronic kidney disease; DD-CKD, dialysis-dependent chronic kidney disease.
Figure 2
Figure 2
Association between HIF stabilizers and ferritin in patients with CKD. Notes: (A) NDD-CKD subgroup. (B) DD-CKD subgroup. Abbreviations: HIF, hypoxia-inducible factor; CKD, chronic kidney disease; NDD-CKD, non-dialysis-dependent chronic kidney disease; DD-CKD, dialysis-dependent chronic kidney disease.
Figure 3
Figure 3
Association between HIF stabilizers and hepcidin in patients with CKD. Notes: (A) NDD-CKD subgroup. (B) DD-CKD subgroup. Abbreviations: HIF, hypoxia-inducible factor; CKD, chronic kidney disease; NDD-CKD, non-dialysis-dependent chronic kidney disease; DD-CKD, dialysis-dependent chronic kidney disease.
Figure 4
Figure 4
Association between HIF stabilizers and TIBC in patients with CKD. Notes: (A) NDD-CKD subgroup. (B) DD-CKD subgroup. Abbreviations: HIF, hypoxia-inducible factor; TIBC, total iron-binding capacity; CKD, chronic kidney disease; NDD-CKD, non-dialysis-dependent chronic kidney disease; DD-CKD, dialysis-dependent chronic kidney disease.
Figure 5
Figure 5
Association between HIF stabilizers and rate of AEs in patients with CKD. Abbreviations: HIF, hypoxia-inducible factor; AEs, adverse events; CKD, chronic kidney disease.
Figure 6
Figure 6
Association between HIF stabilizers and SAEs in patients with CKD. Abbreviations: HIF, hypoxia-inducible factor; SAEs, severe adverse events; CKD, chronic kidney disease.
See this image and copyright information in PMC

References

    1. Hu C, Yang M, Zhu X, et al. Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue. Ther Apher Dial. 2018;22(2):124–132. - PMC - PubMed
    1. Lew QLJ, Allen JC, Nguyen F, Tan NC, Jafar TH. Factors Associated with Chronic Kidney Disease and Their Clinical Utility in Primary Care Clinics in a Multi-Ethnic Southeast Asian Population. Nephron. 2018;138(3):202–213. - PubMed
    1. del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease. Expert Opin Investig Drugs. 2018;27(1):125–133. - PubMed
    1. Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18(1):345. - PMC - PubMed
    1. Riley MV, Vess J, Dumas BP. Home Therapy to Reduce Office Visits for Patients with Chronic Kidney Disease and Anemia. Nephrol Nurs J. 2017;44(1):29–33. - PubMed

Publication types

MeSH terms

Substances